-

12:20:21 PM

RNAZ Stock News

RNAZ - TransCode Therapeutics Inc

02/28/23 7:00 AM

Nasdaq : RNAZ

low float

TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company TM committed to more effectively treating cancer using RNA therapeutics, announced today that it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration

RHEA-AI

very positive

02/22/23 8:00 AM

Nasdaq : RNAZ

low float

TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the signing of a non-binding letter of intent and a joint research and development agreement (JDA)

RHEA-AI

positive

02/16/23 8:00 AM

Nasdaq : RNAZ

offeringlow float

TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase

RHEA-AI

neutral

01/31/23 4:05 PM

Nasdaq : RNAZ

clinical triallow float

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful preclinical

RHEA-AI

neutral

12/29/22 8:00 AM

Nasdaq : RNAZ

clinical triallow float

TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced today that it has received written authorization from the U.S. Food and Drug Administration (FDA) that

RHEA-AI

neutral

12/06/22 4:20 PM

Nasdaq : RNAZ

low float

TransCode Therapeutics Announces Withdrawal of Registration Statement

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it withdrew the Registration Statement on Form S-1 it filed with the U.S.

RHEA-AI

neutral

11/30/22 7:00 AM

Nasdaq : RNAZ

clinical triallow float

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it has submitted an exploratory Investigational New Drug (eIND) application to the U.S. Food

RHEA-AI

neutral

11/14/22 4:15 PM

Nasdaq : RNAZ

low float

TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2022, and recent business progress. “We

RHEA-AI

positive

11/09/22 7:00 AM

Nasdaq : RNAZ

clinical triallow float

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1, in pancreatic

RHEA-AI

neutral

11/07/22 8:00 AM

Nasdaq : RNAZ

conferenceslow float

TransCode Therapeutics to Present at Sidoti Virtual Investor Conference

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it will be presenting at the Sidoti Virtual Conference. TransCode’s Chief Executive Officer,

RHEA-AI

neutral

RNAZ Data

IndustryResearch and Development in Biotechnology
Websitewww.transcodetherapeutics.com
Security nameTransCode Therapeutics Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2834
Employees19

About TransCode Therapeutics Inc

TransCode Therapeutics is an emerging RNA oncology company created to realize its belief that cancer can be defeated through the intelligent design of RNA therapeutics. This belief is based on a new approach to address what TransCode believes has been the most intractable challenge in RNA therapeutics: delivering an oligonucleotide to its target before the body’s immune system can attack and dismantle it. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. TransCode’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which TransCode believes has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. TransCode anticipates submitting an IND, in the second half of 2021 to support initiation of a Phase 0 clinical study with TTX-MC138.